Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia

References

• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ ECOG E2993. Blood 2005;106:3760–3767.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109:944–950.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma 2010;51:475–480.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Estey E, Pluckett W, et al. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 1986;81:387–394.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Walters RS, Keating MJ, et al. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute-lymphoblastic leukemia. Cancer 1990;65:5–8.
   PubMed Web of Science ®Google Scholar
• Arlin ZA, Feldman EJ, Finger LR, et al. Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia 1991;5:712–714.
   PubMed Web of Science ®Google Scholar
• Rosen PJ, Rankin C, Head DR, et al. A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia. Leuk Res 2000;24:183–187.
   PubMed Web of Science ®Google Scholar
• Weiss MA, Drullinsky P, Maslak P, et al. A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia 1998;12:865–868.
   PubMed Web of Science ®Google Scholar
• Weiss MA, Aliff T, Tallman M, et al. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer 2002;95:581–587.
   PubMed Web of Science ®Google Scholar
• Giona F, Testi AM, Amadori S, et al. Idarubicin and high dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. Ann Oncol 1990;1:51–55.
   PubMed Web of Science ®Google Scholar
• Giona F, Annino L, Rondelli R, et al. Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol. Br J Haematol 1997;97:896–903.
   PubMed Web of Science ®Google Scholar
• Karbsian-Esfahani M, Wiernik P, Novik Y, et al. Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Cancer 2004;101:1414–1419.
   PubMed Web of Science ®Google Scholar
• Montillo M, Tedeschi A, Centurioni R, et al. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosinearabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Leuk Lymphoma 1997;25:579–582.
   PubMed Web of Science ®Google Scholar
• Koller CA, Kantarjian HM, Thomas D, et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997;11:2039–2044.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine (CI-F-ara-A;2 chloro-2’-fluoro-deoxy-9-beta-D-arabinofuranosyladenine) in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167–1173.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379–2386.
   PubMed Web of Science ®Google Scholar
• Jeha S, Gynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917–1923.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics of pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemia. Clin Cancer Res 2003;9:6335–6442.
   PubMed Web of Science ®Google Scholar
• Cooper T, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Proc Am Assoc Cancer Res 2003;44:142.
   Google Scholar
• Faderl S, Gandhi V, O’Brien S, et al. Results of a phase I–II study of clofarabine in combination with cytarabine (ara-c) in relapsed and refractory leukemias. Blood 2005;105:940–947.
   PubMed Web of Science ®Google Scholar
• Advani A, Gundacker H, Sala-Torra O, et al. Southwest Oncology Group study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukemia. Br J Haematol 2010;151:430–434.
   PubMed Web of Science ®Google Scholar
• Webb MS, Logan P, Kanter PM, et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 1998;42:461–470.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 2012;31:676–683.
   PubMed Web of Science ®Google Scholar
• A phase 3 study to evaluate Marqibo in the treatment of subjects ≥ 60 years old with newly diagnosed ALL. NCT01439347. Available from: www.clinicaltrials.gov
   Google Scholar
• Hyper-CVAD with liposomal vincristine in acute lymphoblastic leukemia. NCT01319981. Available from: www.clinicaltrials.gov
   Google Scholar
• Kumatori A, Tanaka K, Inamura N, et al. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990;87:7071–7075.
   PubMed Web of Science ®Google Scholar
• Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Can Res 2004;10: 3371–3376.
   PubMed Web of Science ®Google Scholar
• Pigneux A, Mahon F, Moreau-Gaudry F, et al. Proteasome inhibition specifically sensitizes leukemic cells to anthracycline induced apoptosis through accumulation of bim and bax pro-apoptotic proteins. Cancer Bio Ther 2007;6:603–611.
   PubMed Web of Science ®Google Scholar
• Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the Therapeutic Advances in Childhood Leukemia (TACL) consortium. Pediatr Blood Cancer 2010;55:254–259.
   PubMed Web of Science ®Google Scholar
• Messinger Y, Gaynon P, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study. Blood 2012;120:285–290.
   PubMed Web of Science ®Google Scholar
• Bortezomib and combination chemotherapy in treating patients with relapsed or refractory acute lymphoblastic leukemia. NCT01769209. Available from: www.clinicaltrials.gov
   Google Scholar
• Gandhi V, Keating MJ, Bate G, et al. Nelarabine. Nat Rev Drug Discov 2006;5:17–18.
   PubMed Web of Science ®Google Scholar
• Gravatt LC, Chaffee S, Hebert ME, et al. Efficacy and toxicity of 9-beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T-cells from murine bone marrow: application to an in vivo T-leukemia model. Leukemia 1993;7:1261–1267.
   PubMed Web of Science ®Google Scholar
• Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005;23: 3396–3403.
   PubMed Web of Science ®Google Scholar
• Berg SL, Blaney SM, Bernstein M, et al. Activity of compound 506U78 in patients with refractory T-cell malignancies: a POG/CCG intergroup phase 2 study. Blood 2003;102(Suppl. 1): Abstract 792.
   Google Scholar
• DeAngelo DJ, Yu D, Johnson J, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007;109:5136–5142.
   PubMed Web of Science ®Google Scholar
• Pharmacokinetic and pharmacodynamic study of nelarabine in patients with relapsed/refractory lymphoid malignancies. NCT01094860. Available from: clinicaltrials.gov
   Google Scholar
• Gökbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood 2011;118:3504–3511.
   PubMed Web of Science ®Google Scholar
• Raponi S, Stefania De Propris M, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011;52:1098–1107.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 2009;113:6330–6337.
   PubMed Web of Science ®Google Scholar
• Maury S, Huguet F, Leguay T, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica 2010;95:324–328.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Schumich A, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 2008;112:3982–3988.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29(Suppl. 2):2–9.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010;28:3880–3889.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20 + B-Lineage standard and high risk patients; results of 263 CD20 + patients studied prospectively in GMALL study 07/2003. Blood 2010;116(Suppl. 1): Abstract 170.
   PubMed Web of Science ®Google Scholar
• Rowan W, Tite J, Topley P, et al. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998;95:427–436.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Masuyama J, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4 + regulatory T cells. Clin Immunol 2006;120:247–259.
   PubMed Web of Science ®Google Scholar
• Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009;128:260–270.
   PubMed Web of Science ®Google Scholar
• Stock W, Sanford B, Lozanski G, et al. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B study (CALGB 10102). Blood 2009;114(Suppl. 1): Abstract 838.
   Google Scholar
• Angiolillo AL, Yu AL, Reaman G, et al. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr Blood Cancer 2009;53:978–983.
   PubMed Web of Science ®Google Scholar
• Alemtuzumab (CAMPATH 1H) associated to G-CSF in adult patients with refractory acute lymphocytic leukemia. NCT0073149. Available from: www.clinicaltrials.gov
   Google Scholar
• Alemtuzumab and clofarabine for relapsed or refractory acute lymphoblastic leukemia. NCT00983528. Available from: www.clinicaltrials.gov
   Google Scholar
• Combination chemotherapy and alemtuzumab in treating patients with relapsed or refractory acute lymphoblastic leukemia. NCT00262925. Available from: www.clinicaltrials.gov
   Google Scholar
• Poe JC, Fujimoto Y, Hasegawa M, et al. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol 2004;5:1078–1087.
   PubMed Web of Science ®Google Scholar
• Paietta E, Li X, Richards S, et al. Implications for the use of monoclonal antibodies in future adult ALL trials: analysis of antigen expression in 505 B-lineage ALL patients on the MRC UKALLXII/ECOG2993 Intergroup Trial. Blood 2008;112(Suppl. 1): Abstract 1907.
   Google Scholar
• Shih LB, Lu HH, Xuan H, et al. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 1994;56:538–545.
   PubMed Web of Science ®Google Scholar
• Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol 2008;26:3756–3762.
   PubMed Web of Science ®Google Scholar
• Raetz E, Cairo M, Borowitz M, et al. Reinduction chemoimmunotherapy with epratzumab in relapsed acute lymphoblastic leukemia in children, adolescents and young adults: results from Children's Oncology Group Study ADVL04P2. Blood 2011;118(Suppl. 1): Abstract 573.
   PubMed Web of Science ®Google Scholar
• Advani A, McDonough S, Coutre S, et al. Southwest Oncology Group study S0910: a phase 2 trial of clofarabine/cytarabine/epratzumab for relapsed/refractory acute lymphocytic leukemia. Blood 2012;120(Suppl. 1): Abstract 2603.
   Google Scholar
• Dijoseph JF, Dougher MM, Armellino DC, et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007;21:2240–2245.
   PubMed Web of Science ®Google Scholar
• de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 2012;26:255–264.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012;13:403–411.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Thomas D, Jorgensen J, et al. Experience with 2 dose schedules of inotuzumab ozogamicin, single dose, and weekly, in refractory-relapsed acute lymphocytic leukemia (ALL). Blood 2012;120(Suppl. 1): Abstract 671.
   Google Scholar
• DeAngelo D, Stock W, Petersdorf S, et al. Weekly inotuzumab ozogamicin in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia. Blood 2012;120(Suppl. 1): Abstract 2612.
   Google Scholar
• Khouri I, et al. CMC-544 and allogeneic transplantation for CD22 positive-lymphoid malignancies. NCT01664910. Available from: www.clinicaltrials.gov
   Google Scholar
• Study evaluating inotuzumab ozogamicin in acute lymphocytic leukemia. NCT01363297. Available from: www.clinicaltrials.gov
   Google Scholar
• A study of inotuzumab ozogamicin versus investigator's choice of chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia. NCT01564784. Available from: www.clinicaltrials.gov
   Google Scholar
• Kantarjian H, et al. Inotuzumab ozogamycin in elderly acute lymphoblastic leukemia (ALL). NCT01371630. Available from: www.clinicaltrials.gov
   Google Scholar
• Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18: 385–397.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005;15:98–104.
   Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974–977.
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy- refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493–2498.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185–5187.
   PubMed Web of Science ®Google Scholar
• Topp MS, Goekbuget N, Zugmaier G, et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia. Blood 2012; 120(Suppl. 1): Abstract 670.
   PubMed Web of Science ®Google Scholar
• Clinical study with blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). NCT01466179. Available from: www.clinicaltrials.gov
   Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725–733.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
   Google Scholar
• Grupp S, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509–1518.
   PubMed Web of Science ®Google Scholar
• Brentjens R, Davila M, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra38.
   Google Scholar
• Brentuximab vedotin in patients with CD30-positive nonlymphomatous malignancies. NCT01461538. Available from: clinicaltrials.gov
   Google Scholar
• Chevallier P, Robillard N, Charbonnier A, et al. Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL:results of a phase II GRAALL study. Blood 2012;119:2474–2477.
   PubMed Web of Science ®Google Scholar
• Brüggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006;107: 1116–1123.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Leuk Lymphoma 2010;51:475–480.
   PubMed Web of Science ®Google Scholar